Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of INCA00186 alone or with retifanlimab and/or INCB106385 in advanced solid tumors
NL-OMON53794Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inca00186 in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 5 more, sponsored by Incyte. Started Feb 2023; status: active, not recruiting.
02
Drugs
inca00186
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON53794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53794.